A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo

Participants who were randomized to the GA 40 mg treatment arm in the Double-Blind Period,
continue that treatment in the Open-Label Extension Period and are referred to as "Early
Start" participants. Participants randomized to the Placebo arm in the Double-Blind Period
and switched to GA 40 mg subcutaneous injections three times a week in the Open-Label
Extension are referred to as "Delayed Start" participants.

Inclusion Criteria:

1. Subjects must have a confirmed and documented MS diagnosis as defined by the Revised
McDonald criteria with a relapsing-remitting disease course.

2. Subjects must be ambulatory with an EDSS score of 0-5.5 in both screening and baseline
visits.

3. Subjects must be in a relapse-free, stable neurological condition and free of
corticosteroid treatment [intravenous (IV), intramuscular (IM) and/or per os (PO)] or
ACTH 30 days prior to screening (month -1) and between screening and baseline (month
0) visits.

4. Subjects must have experienced one of the following:

At least one documented relapse in the 12 months prior to screening, or At least two
documented relapses in the 24 months prior to screening, or One documented relapse
between 12 and 24 months prior to screening with at least one documented T1-Gd
enhancing lesion in an MRI performed within 12 months prior to screening.

5. Subjects must be between 18 and 55 years of age, inclusive.

6. Women of child-bearing potential must practice an acceptable method of birth control.

7. Subjects must be able to sign and date a written informed consent prior to entering
the study.

8. Subjects must be willing and able to comply with the protocol requirements for the
duration of the study

Exclusion Criteria:

1. Subjects with progressive forms of MS.

2. Use of experimental or investigational drugs, and/or participation in drug clinical
studies within the 6 months prior to screening.

3. Use of immunosuppressive (including Mitoxantrone and Fingolimod) or cytotoxic agents
within 6 months prior to the screening visit.

4. Use of natalizumab (Tysabri®) or any other monoclonal antibodies within 2 years prior
to screening.

5. Use of cladribine within 2 years prior to screening.

6. Previous treatment with immunomodulators (including IFNβ 1a and 1b, and IV
Immunoglobulin (IVIg) within 2 months prior to screening.

7. Previous use of GA or any other glatiramoid.

8. Chronic (more than 30 consecutive days) systemic (IV, PO or IM) corticosteroid
treatment within 6 months prior to screening visit.

9. Previous total body irradiation or total lymphoid irradiation.

10. Previous stem-cell treatment, autologous bone marrow transplantation or allogenic bone
marrow transplantation.

11. Pregnancy or breastfeeding.

12. Subjects with a clinically significant or unstable medical or surgical condition that
would preclude safe and complete study participation, as determined by medical
history, physical exams, ECG, abnormal laboratory tests and chest X-ray. Such
conditions may include hepatic, renal or metabolic diseases, systemic disease, acute
infection, current malignancy or recent history (5 years) of malignancy, major
psychiatric disorder, history of drug and/or alcohol abuse and allergies that could be
detrimental according to the investigator's judgment.

13. A known history of sensitivity to Gadolinium.

14. Inability to successfully undergo MRI scanning.

15. A known drug hypersensitivity to Mannitol.